Exact Mass: 397.3093

Exact Mass Matches: 397.3093

Found 177 metabolites which its exact mass value is equals to given mass value 397.3093, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Solanidine

(2S,4AR,4BS,6as,6BR,7S,7ar,10S,12as,13as,13BS)-4a,6a,7,10-tetramethyl-2,3,4,4a,4b,5,6,6a,6b,7,7a,8,9,10,11,12a,13,13a,13b,14-icosahydro-1H-naphtho[2,1:4,5]indeno[1,2-b]indolizin-2-ol

C27H43NO (397.3344)


Solanidine is a steroid alkaloid fundamental parent, a 3beta-hydroxy-Delta(5)-steroid and a solanid-5-en-3-ol. It has a role as a plant metabolite and a toxin. It is a conjugate base of a solanidine(1+). Solanidine is a natural product found in Fritillaria delavayi, Fritillaria tortifolia, and other organisms with data available. Alkaloid from potato (Solanum tuberosum). Glycosides, (especies Solanines and chaconine) are trace toxic constits. of potato tubers (especies greened tubers), and interbreeding of potatoes with wild strains may increase their concn. or introduce other more toxic, solanidine glycosides Solanidine is a steroidal alkaloid, and its glycosides have been reported to have caused poisoning in man and animals. Solanidine is present in sera of healthy individuals and in amounts dependent on their dietary potato consumption. (PMID: 4007882). Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect[1]. Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect[1].

   

3,4-dihydroxy-2-methyl-4-farnesyl-3H-quinolin-1-ium-1-olate

3,4-Dihydroxy-2-methy-4-[(2E,6E)-farnesyl]-3,4-dihydroquinoline 1-oxide

C25H35NO3 (397.2617)


A member of the class of quinoline N-oxides that is 2-methyl-1-oxo-4-3,4-dihydroquinoline-3,4-diol carrying an additional (2E,6E)-farnesyl group at position 4.

   

trans-Hexadec-2-enoyl carnitine

3-[(2E)-hexadec-2-enoyloxy]-4-(trimethylazaniumyl)butanoate

C23H43NO4 (397.3192)


trans-Hexadec-2-enoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] trans-Hexadec-2-enoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

Phytosphingosine-1-P

{[(2R,3R,4R)-2-amino-3,4-dihydroxyoctadecyl]oxy}phosphonic acid

C18H40NO6P (397.2593)


Phytosphingosine-1-P is an intermediate in sphingolipid metabolism pathway. It is the enzymatic oxidation product of 4-hydroxysphinganine. Sphingolipids are essential components of the plasma membrane in all eukaryotic cells. S. cerevisiae cells make three complex sphingolipids: inositol-phosphoceramide (IPC), mannose-inositol-phosphoceramide (MIPC), and mannosyl-diinositol-phosphorylceramide (M(IP)2C) [ Dickson02 ]. In the yeast plasma membrane sphingolipids concentrate with ergosterol to form lipid rafts, specialized membrane microdomains implicated in a variety of cellular processes, including sorting of membrane proteins and lipids, as well as organizing and regulating signaling cascades [ Bagnat02 ]. Intermediates in sphingolipid biosynthesis have been shown to play important roles as signaling molecules and growth regulators. Sphingolipid long chain bases (LCBs), dihydrosphingosine (DHS) and phytosphingosine (PHS), have been implicated as secondary messengers in signaling pathways that regulate heat stress response. Other intermediates, phytoceramide and long-chain base phosphates (LCBPs), have been shown to be components of tightly-controlled ceramide/LCBP rheostat, which regulates cell growth. Since phosphoinositol-containing sphingolipids are unique to fungi, the sphingolipid biosynthesis pathway is considered a target for antifungal drugs. Phytosphingosine-1-p, also known as phs-1-phosphate, is a member of the class of compounds known as phosphosphingolipids. Phosphosphingolipids are sphingolipids with a structure based on a sphingoid base that is attached to a phosphate head group. They differ from phosphonospingolipids which have a phosphonate head group. Phytosphingosine-1-p is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Phytosphingosine-1-p can be found in a number of food items such as dandelion, common verbena, turmeric, and fennel, which makes phytosphingosine-1-p a potential biomarker for the consumption of these food products.

   

9-Hexadecenoylcarnitine

(3R)-3-[(9Z)-Hexadec-9-enoyloxy]-4-(trimethylazaniumyl)butanoic acid

C23H43NO4 (397.3192)


9-Hexadecenoylcarnitine is an acylcarnitine. More specifically, it is an 9-hexadecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hexadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-hexadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 9-hexadecenoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). 9-Hexadecenoylcarnitine is found to be associated with glutaric aciduria II, which is an inborn error of metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane.  Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Behenoylglycine

2-Docosanamidoacetic acid

C24H47NO3 (397.3556)


Behenoylglycine is an acylglycine with C-20 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. Behenoylglycine is an acylglycine with C-20 fatty acid group as the acyl moiety.

   

PGF2a ethanolamide

(5E)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-N-(2-hydroxyethyl)hept-5-enimidate

C22H39NO5 (397.2828)


PGF2a ethanolamide is a N-acylethanolamine. N-acylethanolamines (NAEs) constitute a class of lipid compounds naturally present in both animal and plant membranes as constituents of the membrane-bound phospholipid, N-acylphosphatidylethanolamine (NAPE). NAPE is composed of a third fatty acid moiety linked to the amino head group of the commonly occurring membrane phospholipid, phosphatidylethanolamine. NAEs are released from NAPE by phospholipase D-type hydrolases in response to a variety of stimuli. Transient NAE release and accumulation has been attributed a variety of biological activities, including neurotransmission, membrane protection, and immunomodulation in animals. N-oleoylethanolamine is an inhibitor of the sphingolipid signaling pathway, via specific ceramidase inhibition (ceramidase converts ceramide to sphingosine). N-oleoylethanolamine blocks the effects of TNF- and arachidonic acid on intracellular Ca concentration. (PMID: 12692337, 12056855, 12560208, 11997249) [HMDB] PGF2a ethanolamide is a N-acylethanolamine. N-acylethanolamines (NAEs) constitute a class of lipid compounds naturally present in both animal and plant membranes as constituents of the membrane-bound phospholipid, N-acylphosphatidylethanolamine (NAPE). NAPE is composed of a third fatty acid moiety linked to the amino head group of the commonly occurring membrane phospholipid, phosphatidylethanolamine. NAEs are released from NAPE by phospholipase D-type hydrolases in response to a variety of stimuli. Transient NAE release and accumulation has been attributed a variety of biological activities, including neurotransmission, membrane protection, and immunomodulation in animals. N-oleoylethanolamine is an inhibitor of the sphingolipid signaling pathway, via specific ceramidase inhibition (ceramidase converts ceramide to sphingosine). N-oleoylethanolamine blocks the effects of TNF- and arachidonic acid on intracellular Ca concentration. (PMID: 12692337, 12056855, 12560208, 11997249).

   

O-Palmitoleoylcarnitine

3-[(9Z)-Hexadec-9-enoyloxy]-4-(trimethylammonio)butanoic acid

C23H43NO4 (397.3192)


O-Palmitoleoylcarnitine is an acylcarnitine. More specifically, it is an palmitoleic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-Palmitoleoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-Palmitoleoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular O-Palmitoleoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(11Z)-Hexadecenoylcarnitine

3-(hexadec-11-enoyloxy)-4-(trimethylazaniumyl)butanoate

C23H43NO4 (397.3192)


(11Z)-Hexadecenoylcarnitine is an acylcarnitine. More specifically, it is an (11Z)-hexadec-11-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z)-Hexadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z)-Hexadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (11Z)-Hexadecenoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z)-Hexadecenoylcarnitine

3-(hexadec-6-enoyloxy)-4-(trimethylazaniumyl)butanoate

C23H43NO4 (397.3192)


(6Z)-Hexadecenoylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-hexadec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-Hexadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z)-Hexadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (6Z)-Hexadecenoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hexadecenoylcarnitine

3-(hexadec-4-enoyloxy)-4-(trimethylazaniumyl)butanoate

C23H43NO4 (397.3192)


4-Hexadecenoylcarnitine is an acylcarnitine. More specifically, it is an hexadec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hexadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-Hexadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 4-Hexadecenoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Hexadecenoylcarnitine

3-(Hexadec-7-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C23H43NO4 (397.3192)


7-Hexadecenoylcarnitine is an acylcarnitine. More specifically, it is an hexadec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hexadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Hexadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 7-Hexadecenoylcarnitine is elevated in the blood or plasma of individuals with children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with familial Mediterranean fever (PMID: 29900937). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Stearoyl Isoleucine

3-methyl-2-octadecanamidopentanoic acid

C24H47NO3 (397.3556)


N-stearoyl isoleucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Isoleucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Isoleucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Isoleucine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Stearoyl Leucine

2-[(1-Hydroxyoctadecylidene)amino]-4-methylpentanoate

C24H47NO3 (397.3556)


N-stearoyl leucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Leucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Leucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Leucine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Oleoyl Aspartic acid

2-(octadec-9-enamido)butanedioic acid

C22H39NO5 (397.2828)


N-oleoyl aspartic acid, also known as N-oleoyl aspartate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

AMP-Deoxynojirimycin

2R-(hydroxymethyl)-1-[5-(tricyclo[3.3.2.13,7]dec-1-ylmethoxy)pentyl]-3R,4R,5S-piperidinetriol

C22H39NO5 (397.2828)


   

N-Hexanoylsphingosine

N-(1,3-dihydroxyoctadec-4-en-2-yl)hexanamide

C24H47NO3 (397.3556)


   

Hexadecenoylcarnitine

3-Hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]nonadec-5-enoic acid

C23H43NO4 (397.3192)


   

Veralomidine

Veralomidine

C27H43NO (397.3344)


   

Shinonomenine

Shinonomenine

C27H43NO (397.3344)


   

Verazine

(20S,25S)-22,26-iminocholesta-5,22(N)-dien-3beta-ol

C27H43NO (397.3344)


   

Buxaquamarine

Buxaquamarine

C26H39NO2 (397.2981)


   
   

C6-Ceramide; N-Hexanoylsphingosine

C6-Ceramide; N-Hexanoylsphingosine

C24H47NO3 (397.3556)


   
   
   
   

octadeca-9,12,15-trienoylanthranilic acid

octadeca-9,12,15-trienoylanthranilic acid

C25H35NO3 (397.2617)


   

dysidaminone B

dysidaminone B

C26H39NO2 (397.2981)


   
   

(2E,12E)-pipertridecadienamide

(2E,12E)-pipertridecadienamide

C25H35NO3 (397.2617)


   

dysidaminone F

dysidaminone F

C26H39NO2 (397.2981)


   

dysidaminone L

dysidaminone L

C26H39NO2 (397.2981)


   

N-3-Methoxybenzyl9Z,12Z,15Z-octadeca-9,12,15-trienamide

N-3-Methoxybenzyl9Z,12Z,15Z-octadeca-9,12,15-trienamide

C26H39NO2 (397.2981)


   

Solanidin

Solanidine

C27H43NO (397.3344)


Origin: Plant; Formula(Parent): C27H43NO; Bottle Name:Solanidine; PRIME Parent Name:Solanidine; PRIME in-house No.:S0346; SubCategory_DNP: The sterols, Cholestanes Bottle Name:Solanidine; Origin: Plant; Formula(Parent): C27H43NO; PRIME Parent Name:Solanidine; PRIME in-house No.:S0346; SubCategory_DNP: The sterols, Cholestanes Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect[1]. Solanidine is a cholestane alkaloid isolated from several potato species including Solanum demissum, Solanum acaule, and Solanum tuberosum. Solanidine can inhibit proliferation and exhibit obvious antitumor effect[1].

   

cyclobuxophylline K

cyclobuxophylline K

C27H43NO (397.3344)


   

CHEMBL4559665

CHEMBL4559665

C22H39NO5 (397.2828)


   

Alprostadil ethanolamide

Alprostadil ethanolamide

C22H39NO5 (397.2828)


   

FZ9FWW7N2Q

9,12,15-Octadecatrienamide, N-((3-methoxyphenyl)methyl)-, (9Z,12Z,15Z)-

C26H39NO2 (397.2981)


N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a natural product found in Lepidium meyenii with data available. See also: Lepidium meyenii root (part of). N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii?Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis[1].

   

Solanidine (not validated)

Solanidine (not validated)

C27H43NO (397.3344)


Annotation level-2

   

Phytosphingosine-1-P

Phytosphingosine-1-P

C18H40NO6P (397.2593)


   

PGF2α-EA

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828)


   

PC(O-9:0/O-1:0)[U]

3,5,9-Trioxa-4-phosphaoctadecan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide

C18H40NO6P (397.2593)


   

Ethanolamide

N-(2-hydroxyethyl)-9α,11β,15S-trihydroxy-prosta-5Z,13E-dien-1-amide

C22H39NO5 (397.2828)


   

AMP-Deoxynojirimycin

2R-(hydroxymethyl)-1-[5-(tricyclo[3.3.2.13,7]dec-1-ylmethoxy)pentyl]-3R,4R,5S-piperidinetriol

C22H39NO5 (397.2828)


   

Prostaglandin E1 Ethanolamide

N-(2-hydroxyethyl)-9-oxo-11α,15S-dihydroxy-prost-13E-en-1-amide

C22H39NO5 (397.2828)


   

PGF2alpha-EA(d4)

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine(d4)

C22H39NO5 (397.2828)


   

11beta-PGF2alpha-EA

N-(9S,11S,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828)


   

8-iso-PGF2alpha III-EA

N-([8S,12R]9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828)


   

PhS1P

(2S,3S,4R)-2-amino-3,4-dihydroxyoctadecyl dihydrogen phosphate

C18H40NO6P (397.2593)


   

trans-2-Hexadecenoyl-carnitine

trans-Hexadec-2-enoyl carnitine

C23H43NO4 (397.3192)


   

PHS-1-Phosphate

Phytosphingosine-1-P

C18H40NO6P (397.2593)


   

C-6 Ceramide

N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-hexanamide

C24H47NO3 (397.3556)


   

PGE1-EA

N-(9-oxo-11R,15S-dihydroxy-13E-prostenoyl)-ethanolamine

C22H39NO5 (397.2828)


   

PMF2alpha

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine

C22H39NO5 (397.2828)


   

CAR 16:1

(9Z)-hexadec-9-enoylcarnitine;3-[(9Z)-hexadec-9-enoyloxy]-4-(trimethylammonio)butanoate;cis-9-hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

20-epi-Verazine

(20R,25S)-22,26-iminocholesta-5,22(N)-dien-3beta-ol

C27H43NO (397.3344)


   

stearoyl leucine

Leucine, N-stearoyl-, L-

C24H47NO3 (397.3556)


   

(+)-MK801MALEATE

(+)-MK801MALEATE

C22H39NO3S (397.2651)


   

Ceramides Mixture

Ceramides Mixture

C24H47NO3 (397.3556)


   

N-docosanoylglycine

N-docosanoylglycine

C24H47NO3 (397.3556)


An N-acylglycine in which the acyl group is specified as docosanoyl.

   

PGF2alpha-ethanolamine(d4)

PGF2alpha-ethanolamine(d4)

C22H39NO5 (397.2828)


   

(1S,2R,10S,11S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracosan-7-one

(1S,2R,10S,11S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracosan-7-one

C27H43NO (397.3344)


   

N-hexanoyl-D-erythro-sphingosine

N-hexanoyl-D-erythro-sphingosine

C24H47NO3 (397.3556)


   

O-palmitoleoyl-l-carnitine

O-palmitoleoyl-l-carnitine

C23H43NO4 (397.3192)


   

trans-2-Hexadecenoylcarnitine

trans-2-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

N-Oleoyl Aspartic acid

N-Oleoyl Aspartic acid

C22H39NO5 (397.2828)


   

4-Hexadecenoylcarnitine

4-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

7-Hexadecenoylcarnitine

7-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

(6Z)-Hexadecenoylcarnitine

(6Z)-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

(11Z)-Hexadecenoylcarnitine

(11Z)-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

N-Hexanoylsphingosine

N-(hexanoyl)sphing-4-enine

C24H47NO3 (397.3556)


   

9-Hexadecenoylcarnitine

9-Hexadecenoylcarnitine

C23H43NO4 (397.3192)


   

1-[1-(cyclooctylmethyl)-5-(hydroxymethyl)-3,6-dihydro-2H-pyridin-4-yl]-3-ethyl-2-benzimidazolone

1-[1-(cyclooctylmethyl)-5-(hydroxymethyl)-3,6-dihydro-2H-pyridin-4-yl]-3-ethyl-2-benzimidazolone

C24H35N3O2 (397.2729)


   

1-Decyl-sn-glycero-3-phosphocholine

1-Decyl-sn-glycero-3-phosphocholine

C18H40NO6P (397.2593)


   

(5S)-5-(2-methylpropyl)-3-[(2E,6R,8E,10E,12E)-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraenoyl]-2,5-dihydro-1H-pyrrol-2-one

(5S)-5-(2-methylpropyl)-3-[(2E,6R,8E,10E,12E)-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraenoyl]-2,5-dihydro-1H-pyrrol-2-one

C26H39NO2 (397.2981)


   

3-{[(1S,2R,4aR,6R,8aS)-2-(but-2-en-2-yl)-3,4a,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](hydroxy)methylidene}-5-(2-methylpropyl)-2,3-dihydro-1H-pyrrol-2-one

3-{[(1S,2R,4aR,6R,8aS)-2-(but-2-en-2-yl)-3,4a,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl](hydroxy)methylidene}-5-(2-methylpropyl)-2,3-dihydro-1H-pyrrol-2-one

C26H39NO2 (397.2981)


   

(3Z)-3-[(2E,6R,8E,10E,12E)-1-hydroxy-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraen-1-ylidene]-5-(2-methylpropyl)-2,3-dihydro-1H-pyrrol-2-one

(3Z)-3-[(2E,6R,8E,10E,12E)-1-hydroxy-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraen-1-ylidene]-5-(2-methylpropyl)-2,3-dihydro-1H-pyrrol-2-one

C26H39NO2 (397.2981)


   

(5S)-3-[(1S,2R,4aR,6R,8aS)-2-(but-2-en-2-yl)-3,4a,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-2,5-dihydro-1H-pyrrol-2-one

(5S)-3-[(1S,2R,4aR,6R,8aS)-2-(but-2-en-2-yl)-3,4a,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-2,5-dihydro-1H-pyrrol-2-one

C26H39NO2 (397.2981)


   

[(1S)-1-(cyclopentylmethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

[(1S)-1-(cyclopentylmethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C24H35N3O2 (397.2729)


   

(3-Decoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Decoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C18H40NO6P (397.2593)


   

2-Aminoethyl (2-hydroxy-3-tridecoxypropyl) hydrogen phosphate

2-Aminoethyl (2-hydroxy-3-tridecoxypropyl) hydrogen phosphate

C18H40NO6P (397.2593)


   

N-[(E)-1,3-dihydroxyhenicos-4-en-2-yl]propanamide

N-[(E)-1,3-dihydroxyhenicos-4-en-2-yl]propanamide

C24H47NO3 (397.3556)


   

(Z)-N-(1,3-dihydroxynonan-2-yl)pentadec-9-enamide

(Z)-N-(1,3-dihydroxynonan-2-yl)pentadec-9-enamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]hexadecanamide

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]hexadecanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]heptanamide

N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]heptanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]octanamide

N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]octanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]nonanamide

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]nonanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxynon-4-en-2-yl]pentadecanamide

N-[(E)-1,3-dihydroxynon-4-en-2-yl]pentadecanamide

C24H47NO3 (397.3556)


   

(Z)-N-(1,3-dihydroxyoctan-2-yl)hexadec-9-enamide

(Z)-N-(1,3-dihydroxyoctan-2-yl)hexadec-9-enamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxyicos-4-en-2-yl]butanamide

N-[(E)-1,3-dihydroxyicos-4-en-2-yl]butanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxydocos-4-en-2-yl]acetamide

N-[(E)-1,3-dihydroxydocos-4-en-2-yl]acetamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxynonadec-4-en-2-yl]pentanamide

N-[(E)-1,3-dihydroxynonadec-4-en-2-yl]pentanamide

C24H47NO3 (397.3556)


   

(Z)-N-(1,3-dihydroxydecan-2-yl)tetradec-9-enamide

(Z)-N-(1,3-dihydroxydecan-2-yl)tetradec-9-enamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]undecanamide

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]undecanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]decanamide

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]decanamide

C24H47NO3 (397.3556)


   

(Z)-N-(1,3-dihydroxyundecan-2-yl)tridec-9-enamide

(Z)-N-(1,3-dihydroxyundecan-2-yl)tridec-9-enamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]tridecanamide

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]tridecanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxydec-4-en-2-yl]tetradecanamide

N-[(E)-1,3-dihydroxydec-4-en-2-yl]tetradecanamide

C24H47NO3 (397.3556)


   

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]dodecanamide

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]dodecanamide

C24H47NO3 (397.3556)


   

(14xi,22xi)-Solanid-5-en-3-ol

(14xi,22xi)-Solanid-5-en-3-ol

C27H43NO (397.3344)


   

N-(decanoyl)-4E-tetradecasphingenine

N-(decanoyl)-4E-tetradecasphingenine

C24H47NO3 (397.3556)


   

N-[(E,2S,3R)-1,3-dihydroxytetradec-8-en-2-yl]decanamide

N-[(E,2S,3R)-1,3-dihydroxytetradec-8-en-2-yl]decanamide

C24H47NO3 (397.3556)


   

Phytosphingosine 1-phosphate

Phytosphingosine 1-phosphate

C18H40NO6P (397.2593)


A phosphosphingolipid that is phytosphingosine bearing a phospho group at position 1.

   

(2E)-hexadecenoylcarnitine

(2E)-hexadecenoylcarnitine

C23H43NO4 (397.3192)


An O-hexadecenoylcarnitine having (2E)-hexadecenoyl as the acyl substituent.

   

PGF2a ethanolamide

PGF2a ethanolamide

C22H39NO5 (397.2828)


   

O-palmitoleoylcarnitine

O-palmitoleoylcarnitine

C23H43NO4 (397.3192)


An O-acylcarnitine having palmitoleoyl as the acyl substituent.

   
   

Solanid-5-en-3-ol

Solanid-5-en-3-ol

C27H43NO (397.3344)


A 3-hydroxy steroid that is solanid-5-ene substituted by a hydroxy group at position 3.

   

O-hexadecenoylcarnitine

O-hexadecenoylcarnitine

C23H43NO4 (397.3192)


An O-acylcarnitine having a hexadecenoyl group with an unspecified double bond as the acyl substituent.

   

O-hexadecenoyl-L-carnitine

O-hexadecenoyl-L-carnitine

C23H43NO4 (397.3192)


An O-acyl-L-carnitine that is L-carnitine having a hexadecenoyl group as the acyl substituent in which the position of the double bond is unspecified.

   

N-(hexanoyl)sphing-4-enine

N-(hexanoyl)sphing-4-enine

C24H47NO3 (397.3556)


An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.

   

CarE(16:1)

CarE(16:1)

C23H43NO4 (397.3192)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

NA-2AAA 16:1(9Z)

NA-2AAA 16:1(9Z)

C22H39NO5 (397.2828)


   
   

NA-Amylamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Amylamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C27H43NO (397.3344)


   

NA-Asp 18:1(9Z)

NA-Asp 18:1(9Z)

C22H39NO5 (397.2828)


   

NA-Cit 15:1(9Z)

NA-Cit 15:1(9Z)

C21H39N3O4 (397.294)


   

NA-Glu 17:1(9Z)

NA-Glu 17:1(9Z)

C22H39NO5 (397.2828)


   
   

NA-Histamine 20:4(5Z,8Z,11Z,14Z)

NA-Histamine 20:4(5Z,8Z,11Z,14Z)

C25H39N3O (397.3093)


   
   
   

NA-Met 17:2(9Z,12Z)

NA-Met 17:2(9Z,12Z)

C22H39NO3S (397.2651)


   

NA-PABA 18:3(6Z,9Z,12Z)

NA-PABA 18:3(6Z,9Z,12Z)

C25H35NO3 (397.2617)


   

NA-PABA 18:3(9Z,12Z,15Z)

NA-PABA 18:3(9Z,12Z,15Z)

C25H35NO3 (397.2617)


   

NA-Ser 20:1(11Z)

NA-Ser 20:1(11Z)

C23H43NO4 (397.3192)


   

NA-Thr 19:1(9Z)

NA-Thr 19:1(9Z)

C23H43NO4 (397.3192)


   
   
   
   
   
   
   

Cer 14:1;O2/10:0

Cer 14:1;O2/10:0

C24H47NO3 (397.3556)


   
   

(1s,3as,3br,7s,9ar,9bs)-1,9a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

(1s,3as,3br,7s,9ar,9bs)-1,9a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

n-[(3-methoxyphenyl)methyl]octadeca-9,12,15-trienimidic acid

n-[(3-methoxyphenyl)methyl]octadeca-9,12,15-trienimidic acid

C26H39NO2 (397.2981)


   

13,15-dihydroxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9-dien-11-one

13,15-dihydroxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9-dien-11-one

C25H35NO3 (397.2617)


   

1-[(6r,7s,10s,11r,14r,15r,20r)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

1-[(6r,7s,10s,11r,14r,15r,20r)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

C26H39NO2 (397.2981)


   

(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

(1s,2s,7s,10r,11s,14s,15r,16s,17r,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2s,7s,10r,11s,14s,15r,16s,17r,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1s,2s,7s,10r,11s,14s,15r,16s,17s,20s,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2s,7s,10r,11s,14s,15r,16s,17s,20s,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1r,3ar,3br,7s,9ar,9br,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3ar,3br,7s,9ar,9br,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

(1r,3as,3br,7s,9ar,9bs)-1,9a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3br,7s,9ar,9bs)-1,9a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

(20R)-epi-verazine

NA

C27H43NO (397.3344)


{"Ingredient_id": "HBIN003451","Ingredient_name": "(20R)-epi-verazine","Alias": "NA","Ingredient_formula": "C27H43NO","Ingredient_Smile": "CC1CCC(=NC1)C(C)C2CCC3C2(CCC4C3CC=C5C4(CCC(C5)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "36148","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]heptan-2-yl]oxy}-3-methyl-1-oxobutan-2-yl]carboximidic acid

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]heptan-2-yl]oxy}-3-methyl-1-oxobutan-2-yl]carboximidic acid

C22H39NO5 (397.2828)


   

(1r,3r,6s,8r,11s,12s,15e,16s)-6-(dimethylamino)-15-ethylidene-7,7,11,12,16-pentamethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

(1r,3r,6s,8r,11s,12s,15e,16s)-6-(dimethylamino)-15-ethylidene-7,7,11,12,16-pentamethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

C27H43NO (397.3344)


   

1-{6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl}ethanone

1-{6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl}ethanone

C26H39NO2 (397.2981)


   

o-phosphoethanolamine; bis(nonane)

o-phosphoethanolamine; bis(nonane)

C20H48NO4P (397.3321)


   

1,9a-dimethyl-1-[1-(5-methylpiperidin-2-yl)ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

1,9a-dimethyl-1-[1-(5-methylpiperidin-2-yl)ethyl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

(1r,3s,6s,7z,10s,11s,14r,15s,20s)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

(1r,3s,6s,7z,10s,11s,14r,15s,20s)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

C26H39NO2 (397.2981)


   

11-hydroxy-7-methyl-17-methylidene-5-azahexacyclo[9.6.2.0³,¹⁵.0⁴,¹².0⁷,¹².0¹⁵,¹⁹]nonadec-4-en-14-yl 2-methylbutanoate

11-hydroxy-7-methyl-17-methylidene-5-azahexacyclo[9.6.2.0³,¹⁵.0⁴,¹².0⁷,¹².0¹⁵,¹⁹]nonadec-4-en-14-yl 2-methylbutanoate

C25H35NO3 (397.2617)


   

(1s,2s,7s,10r,11r,14s,15r,16s,17s,20s,23r)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2s,7s,10r,11r,14s,15r,16s,17s,20s,23r)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(1r)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(1r)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

n-[1-(acetyloxy)-3-methoxypropan-2-yl]-2-methylhexadec-2-enimidic acid

n-[1-(acetyloxy)-3-methoxypropan-2-yl]-2-methylhexadec-2-enimidic acid

C23H43NO4 (397.3192)


   

1-[(6r,7s,10s,11r,14r,15s,20s)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

1-[(6r,7s,10s,11r,14r,15s,20s)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

C26H39NO2 (397.2981)


   

1-[(6r,7s,10s,11r,14r,15r,20s)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

1-[(6r,7s,10s,11r,14r,15r,20s)-6,10,15,19-tetramethyl-17-oxa-19-azapentacyclo[12.8.0.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosa-1,3-dien-7-yl]ethanone

C26H39NO2 (397.2981)


   

(1s,2s,7s,10r,11s,14s,15r,16s,17s,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2s,7s,10r,11s,14s,15r,16s,17s,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1s,3r,6r,9e,13s,15r,16r)-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9,11-triene-11,13,15-triol

(1s,3r,6r,9e,13s,15r,16r)-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9,11-triene-11,13,15-triol

C25H35NO3 (397.2617)


   

7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

C26H39NO2 (397.2981)


   

(7z)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

(7z)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

C26H39NO2 (397.2981)


   

(9z,12z,15z)-n-[(3-methoxyphenyl)methyl]octadeca-9,12,15-trienimidic acid

(9z,12z,15z)-n-[(3-methoxyphenyl)methyl]octadeca-9,12,15-trienimidic acid

C26H39NO2 (397.2981)


   

(1s,2r,7r,10s,11r,14r,15r,16s,17r,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2r,7r,10s,11r,14r,15r,16s,17r,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-{1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-{1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

1-{8,10,10,15,19-pentamethyl-6-oxa-8-azapentacyclo[12.7.0.0³,¹¹.0⁵,⁹.0¹⁵,¹⁹]henicosa-1(21),2-dien-18-yl}ethanone

1-{8,10,10,15,19-pentamethyl-6-oxa-8-azapentacyclo[12.7.0.0³,¹¹.0⁵,⁹.0¹⁵,¹⁹]henicosa-1(21),2-dien-18-yl}ethanone

C26H39NO2 (397.2981)


   

6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-17-en-20-ol

6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-17-en-20-ol

C27H43NO (397.3344)


   

(1s,2s,7s,10r,11s,14s,15s,16r,17s,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

(1s,2s,7s,10r,11s,14s,15s,16r,17s,20r,23s)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-ol

C27H43NO (397.3344)


   

(1r,3r,7s,11s,12r,14s,15r,19s)-11-hydroxy-7-methyl-17-methylidene-5-azahexacyclo[9.6.2.0³,¹⁵.0⁴,¹².0⁷,¹².0¹⁵,¹⁹]nonadec-4-en-14-yl (2r)-2-methylbutanoate

(1r,3r,7s,11s,12r,14s,15r,19s)-11-hydroxy-7-methyl-17-methylidene-5-azahexacyclo[9.6.2.0³,¹⁵.0⁴,¹².0⁷,¹².0¹⁵,¹⁹]nonadec-4-en-14-yl (2r)-2-methylbutanoate

C25H35NO3 (397.2617)


   

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1r)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1r)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

(1r,2s,6s,9s,10s,11s,14s,15s,20s,23r,24s)-6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-17-en-20-ol

(1r,2s,6s,9s,10s,11s,14s,15s,20s,23r,24s)-6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-17-en-20-ol

C27H43NO (397.3344)


   

(2e)-n-[(2r)-1-(acetyloxy)-3-methoxypropan-2-yl]-2-methylhexadec-2-enimidic acid

(2e)-n-[(2r)-1-(acetyloxy)-3-methoxypropan-2-yl]-2-methylhexadec-2-enimidic acid

C23H43NO4 (397.3192)


   

(1r,3s,6r,7z,10r,11r,14s,15s,20s)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

(1r,3s,6r,7z,10r,11r,14s,15s,20s)-7-ethylidene-6,10,15,19-tetramethyl-17-oxa-19-azahexacyclo[12.8.0.0¹,³.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰]docosan-8-one

C26H39NO2 (397.2981)


   

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

(1r,3as,3bs,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol

C27H43NO (397.3344)


   

6-(dimethylamino)-15-ethylidene-7,7,11,12,16-pentamethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

6-(dimethylamino)-15-ethylidene-7,7,11,12,16-pentamethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

C27H43NO (397.3344)